What is a low-grade adipocytic (fat cell) lesion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Low-Grade Adipocytic Lesion

A low-grade adipocytic lesion is a benign or locally aggressive tumor composed of fat cells (adipocytes) that exhibits minimal cellular atypia and low malignant potential, most commonly representing either a benign lipoma or an atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WD).

Definition and Classification

Low-grade adipocytic lesions encompass a spectrum of fat-containing tumors characterized by:

  • Benign lipomas: Composed of normal mature adipocytes without MDM2 amplification 1
  • Atypical lipomatous tumors/well-differentiated liposarcoma (ALT/WD): Low-grade, locally aggressive tumors with consistent MDM2 amplification patterns 2, 1
  • Other benign variants: Including lipoblastoma, hibernoma, and spindle cell/pleomorphic lipoma 3, 4

Histological Characteristics

The microscopic features that define low-grade status include:

  • Mature adipocytes with minimal cytologic atypia 5
  • Absence of high-grade features such as marked nuclear pleomorphism, increased mitotic activity, or necrosis 5
  • Relatively uniform cell size lacking significant cytologic atypia 5
  • Simple architectural patterns without complex irregularities 5

Molecular Diagnostic Features

MDM2 amplification testing is the critical molecular tool for distinguishing benign from atypical low-grade lesions:

  • Benign lipomas: MDM2 negative 1
  • ALT/WD: MDM2 amplification present in essentially all cases 2, 1
  • Studies demonstrate 76% positive MDM2 testing rate when clinical suspicion warrants testing 1

Clinical Behavior and Prognosis

Low-grade adipocytic lesions demonstrate distinct behavioral patterns:

  • Benign lipomas: No recurrence or metastatic potential 1
  • ALT/WD: Higher local recurrence rates (10-20% may progress to dedifferentiated form depending on location) but rare metastases 1
  • Location significantly impacts behavior—peripheral/secondary tumors are usually low grade with infrequent metastasis 5

Treatment Approach

Management is determined by histologic grade and tumor location 5:

  • Resectable low-grade lesions: Intralesional excision with or without adjuvant therapy for smaller, intracompartmental lesions 5
  • Larger or problematic locations: Wide excision with negative margins preferred for larger size, intraarticular, or pelvic localization 5
  • Unresectable lesions: Radiation therapy 5

Surveillance Recommendations

For low-grade lesions, follow-up consists of 5:

  • Physical examination every 6-12 months for 2 years
  • Imaging of the lesion at same intervals
  • Chest radiograph every 6-12 months for 2 years, then yearly as appropriate
  • Extended surveillance warranted as late recurrences can occur 5

Critical Diagnostic Pitfalls

The primary challenge is distinguishing truly benign lipomas from ALT/WD, as both may appear similar clinically but have different recurrence risks 2, 1. MDM2 testing should be performed when:

  • Tumor size is large
  • Deep tissue location is present
  • Imaging characteristics suggest atypia
  • Clinical suspicion exists based on location (retroperitoneum, mediastinum) 1

References

Research

What's new in adipocytic neoplasia?

Virchows Archiv : an international journal of pathology, 2020

Research

[Adipocytic tumors].

Annales de pathologie, 2015

Research

Newly described adipocytic lesions.

Seminars in diagnostic pathology, 2001

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.